News

Randomized clinical studies provide insight on relative efficacy, safety of two aqueous devices

Milestone birthday celebration gets a shot in the arm

Unlock the potential of digital spectacle lenses for your patients, dispensary

Paging through NEJM provides historical perspective of changes in ophthalmology, language

In this video demonstration, Allen M. Putterman, MD indicates how having consecutive instrumentation for conjunctivodacryocystorhinostomy (CDCR) makes a difference.

This stepwise video presentation of the standardized "no-touch" Descemet’s membrane endothelial keratoplasty (DMEK) technique is described by Gerrit R.J. Melles, MD, PhD.

In the following video, Mark Forchette, president and CEO of OptiMedica, discusses how the FDA approval of the Catalys femtosecond laser for creating single-plane and multi-plane arc incisions during cataract surgery, and its subsequent market launch, means to the company.

Use of arcuate incisions in femtosecond laser cataract surgery are highlighted in this brief video presentation from Eric D. Donnenfeld, MD.

Abbott has received FDA approval for its Healon Duet Dual Pack OVD, which includes Healon and Healon EndoCoat OVDs in separate sterile trays.

The American Glaucoma Society (AGS) has chosen Thasarat S. Vajaranant, MD, to receive the Thom J. Zimmerman, MD, PhD Memorial Award, supported by Valeant Ophthalmics.

Ophthalmic Women Leaders (OWL) is now accepting nominations from OWL members for three annual awards, with a deadline of March 15.

Unoprostone isopropyl formulation (Rescula, Sucampo) makes alternative mechanism available for lowering IOP in open-angle glaucoma or ocular hypertension.

OptiMedica Corp. has received a patent for the Catalys Precision Laser System relating to the fundamental technology underlying laser cataract surgery.

Results from quality of life and vision surveys provide insight on patient-based subjective outcomes after bilateral implantation of presbyopia-correcting IOLs.

French physician was the chairman of the Department of Ophthalmology at Bordeaux University Medical School. He received numerous awards, and served on many editorial and other boards.

Optogenetics, a new laboratory development, may be the key to a new therapy for retinitis pigmentosa.

Take-Home MessageInvestors are shifting assets to passively managed vehicles. For many, exchange-traded funds (ETFs) have become the vehicle of choice. ETFs are investments that trade on exchanges, and are designed to mirror the performance of certain market indexes, so they tend to be passively managed.

We doctors should probably always think the best of our patients, honoring and respecting them. But that can be hard sometimes, because they are a bunch of liars. Does this seem a bit harsh to you? Well, a recent review of studies on patient veracity reveals some striking findings.

GALILEO is a sham-controlled pivotal trial investigating the efficacy and safety of aflibercept (Eylea, Bayer/Regeneron Pharmaceuticals) for the treatment of macular edema secondary to central retinal vein occlusion. Primary and secondary efficacy analyses after 6 months of routine monthly injections show consistent statistically significant treatment benefits.